Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy
This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed...
Main Authors: | Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/304 |
Similar Items
-
SYSTEMIC TREATMENT IN DUCTAL CARCINOMA IN SITU
by: Bülent Karagöz, et al.
Published: (2013-04-01) -
Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01) -
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast
by: Yasuaki Sagara, et al.
Published: (2017-08-01) -
Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea
by: Dooreh Kim, et al.
Published: (2023-02-01) -
Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01)